LU93072I2 - Inhibiteur de la protéinase alpha-1 humaine - Google Patents

Inhibiteur de la protéinase alpha-1 humaine Download PDF

Info

Publication number
LU93072I2
LU93072I2 LU93072C LU93072C LU93072I2 LU 93072 I2 LU93072 I2 LU 93072I2 LU 93072 C LU93072 C LU 93072C LU 93072 C LU93072 C LU 93072C LU 93072 I2 LU93072 I2 LU 93072I2
Authority
LU
Luxembourg
Prior art keywords
inhibitor
alpha
human proteinase
proteinase
human
Prior art date
Application number
LU93072C
Other languages
English (en)
Original Assignee
Csl Behring Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32655016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93072(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Llc filed Critical Csl Behring Llc
Publication of LU93072I2 publication Critical patent/LU93072I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
LU93072C 2002-12-31 2016-05-12 Inhibiteur de la protéinase alpha-1 humaine LU93072I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/334,303 US7777006B2 (en) 2002-12-31 2002-12-31 Method for purification of alpha-1-antitrypsin
EP03814875.5A EP1590061B1 (fr) 2002-12-31 2003-12-19 Procede de purification d'antitrypsine alpha-1

Publications (1)

Publication Number Publication Date
LU93072I2 true LU93072I2 (fr) 2016-07-12

Family

ID=32655016

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93072C LU93072I2 (fr) 2002-12-31 2016-05-12 Inhibiteur de la protéinase alpha-1 humaine

Country Status (12)

Country Link
US (8) US7777006B2 (fr)
EP (4) EP3006462B1 (fr)
JP (1) JP5249489B2 (fr)
AU (2) AU2003301108B2 (fr)
CA (1) CA2511986C (fr)
DK (3) DK3006462T3 (fr)
ES (3) ES2564627T3 (fr)
HU (2) HUE027327T2 (fr)
LU (1) LU93072I2 (fr)
PT (1) PT1590061E (fr)
SI (2) SI2295126T1 (fr)
WO (1) WO2004060528A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
WO2005014825A2 (fr) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Procede de production de proteines dans une levure
SI1664123T2 (sl) * 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
WO2007062270A2 (fr) * 2005-11-28 2007-05-31 Proteomtech Inc. Procedes destines a la production d'alpha1-antitrypsine recombinante
GB0524432D0 (en) * 2005-11-30 2006-01-11 Nhs Blood & Transplant Method
US8772240B2 (en) 2006-05-19 2014-07-08 Baxter International Inc. Ethanol dependence of alpha1 antitrypsin C-terminal lys truncation by basic carboxypeptidases
JP5600061B2 (ja) * 2007-08-17 2014-10-01 ツェーエスエル ベーリンク ゲゼルシャフト ミット ベシュレンクテル ハフツング α−１−抗トリプシンおよびアポリポタンパク質Ａ−Ｉを精製する方法
US20110237781A1 (en) * 2008-07-18 2011-09-29 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
ES2679819T3 (es) * 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa
WO2011150284A2 (fr) 2010-05-26 2011-12-01 Baxter International Inc. Élimination de sérine protéases par traitement avec du dioxyde de silicium finement divisé
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
MX344268B (es) * 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
CN102558295A (zh) * 2010-12-28 2012-07-11 同路生物制药有限公司 生产α1抗胰蛋白酶的方法
CN102180966B (zh) * 2011-01-28 2013-04-03 哈尔滨派斯菲科生物制药股份有限公司 一种规模化生产人α1-抗胰蛋白酶的方法
US9353165B2 (en) 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
US9890203B2 (en) * 2013-06-05 2018-02-13 Csl Limited Process for preparing apolipoprotein A-I (Apo A-I)
WO2015070075A1 (fr) * 2013-11-07 2015-05-14 Medical Discovery Partners Llc Témoins quantitatifs et étalonneurs pour analytes cellulaires
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN107163138B (zh) * 2017-03-28 2021-02-09 深圳市卫光生物制品股份有限公司 一种人血浆蛋白α1-抗胰蛋白酶的分离纯化方法
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
WO2021054999A1 (fr) * 2019-09-20 2021-03-25 Plasma Technologies, Llc Compositions de protéines thérapeutiques et procédés correspondants
CN112409476B (zh) * 2020-08-13 2022-03-29 中元汇吉生物技术股份有限公司 四种血液来源蛋白的纯化方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE629149A (fr) * 1962-03-03
DE1189674B (de) 1963-06-12 1965-03-25 Behringwerke Ag Verfahren zur Isolierung von alpha-Antitrypsin
US3293326A (en) 1965-07-06 1966-12-20 Sun Oil Co Dyeable interpolymers consisting of alpha-olefins and a nitrogen containing compound
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
JPS584728A (ja) * 1981-05-01 1983-01-11 メデイカル・リサ−チ・インステイチユ−ト・オブ・サンフランシスコ・コ−ポレ−シヨン α−１−抗トリプシンの精製
DE3271827D1 (en) 1981-05-01 1986-07-31 Medical Research Inst Of San F Method for isolating alpha-1-antitrypsin
US4439358A (en) * 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4379087A (en) * 1982-06-17 1983-04-05 Cutter Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
JPS59128335A (ja) 1983-01-12 1984-07-24 Fujirebio Inc α↓１−アンチトリプシンの分離取得方法
US4820805A (en) 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
US4683294A (en) 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4684723A (en) * 1985-09-11 1987-08-04 Miles Laboratories, Inc. Method of separating proteins from aqueous solutions
US4697003A (en) * 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4656254A (en) 1985-12-02 1987-04-07 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor and antithrombin III
US4629567A (en) * 1986-03-07 1986-12-16 Smithkline-Rit Alpha-1-antiprotease purification
DE3615171A1 (de) 1986-05-05 1987-11-12 Hans Ing Grad Kern Einrichtung zum reinigen von rohrleitungen
US4749783A (en) 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
US5114863A (en) 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
FR2610633B1 (fr) 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
ES2053606T3 (es) 1987-04-27 1994-08-01 Miles Inc Metodo de preparacion de un inhibidor de alfa-1-proteinasa de alta pureza.
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
MY105067A (en) 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
ES2063882T5 (es) 1989-10-02 2001-12-01 Novartis Nutrition Ag Hidrolizados de proteinas.
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
FR2672895B1 (fr) * 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
ES2284226T3 (es) 1991-07-02 2007-11-01 Nektar Therapeutics Dispositivo para proporcionar medicamentos en aerosol.
ATE194921T1 (de) 1992-03-02 2000-08-15 Bioeng Inc Verfahren zur inaktivierung von viren
IT1271463B (it) * 1993-12-16 1997-05-28 Sclavo Spa Processo per l'estrazione e purificazione dell'alfal-antitripsina (alfal-pi)dalla frazione iv-1 di cohn.
DE4407837C1 (de) 1994-03-09 1995-08-17 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem alpha¶1¶-Antitrypsin mittels Anionenaustauscher-Chromatographie
US6096216A (en) 1994-06-09 2000-08-01 American National Red Cross Iodinated matrices for disinfecting biological fluids
US6284874B1 (en) 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5616693A (en) * 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US6093804A (en) 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6106773A (en) 1998-09-24 2000-08-22 American National Red Cross Pathogen inactivating compositions for disinfecting biological fluids
US6403646B1 (en) * 1999-06-30 2002-06-11 David H. Perlmutter Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies
US6436344B1 (en) 1999-11-02 2002-08-20 American National Red Cross Method of inactivating pathogens
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
DE10022092A1 (de) * 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
AU2002246668A1 (en) 2000-11-02 2002-07-30 Molecular Discoveries, L.L.C. Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
EP1343809B2 (fr) 2000-12-14 2023-03-15 Grifols Therapeutics Inc. Procede pour l'elaboration d'un inhibiteur de proteinase alpha-1
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US10334303B1 (en) 2014-12-31 2019-06-25 The Directv Group, Inc. Systems and methods for personalized feature setup and parental guidance sensing

Also Published As

Publication number Publication date
US9320783B2 (en) 2016-04-26
US20120165261A1 (en) 2012-06-28
US20200078451A1 (en) 2020-03-12
HUS1600026I1 (hu) 2016-06-28
US9950046B2 (en) 2018-04-24
US8722624B2 (en) 2014-05-13
SI1590061T1 (sl) 2015-06-30
HUE027327T2 (en) 2016-10-28
JP2006512394A (ja) 2006-04-13
US20040124143A1 (en) 2004-07-01
EP3006462B1 (fr) 2019-04-10
EP3006462A1 (fr) 2016-04-13
CA2511986A1 (fr) 2004-07-22
EP2295126B1 (fr) 2015-12-16
SI2295126T1 (sl) 2016-05-31
EP1590061B1 (fr) 2014-08-06
EP1590061A4 (fr) 2006-08-09
ES2564627T3 (es) 2016-03-28
DK3006462T3 (da) 2019-06-17
JP5249489B2 (ja) 2013-07-31
PT1590061E (pt) 2014-10-23
AU2003301108A1 (en) 2004-07-29
US8124736B2 (en) 2012-02-28
HK1152007A1 (en) 2012-02-17
AU2003301108B2 (en) 2009-09-10
US20180200347A1 (en) 2018-07-19
US20100310550A1 (en) 2010-12-09
EP2295126A1 (fr) 2011-03-16
US20170042986A1 (en) 2017-02-16
AU2009248429A1 (en) 2010-01-07
EP1590061A1 (fr) 2005-11-02
DK1590061T3 (da) 2014-10-13
US10335467B2 (en) 2019-07-02
AU2009248429B2 (en) 2012-02-23
ES2515816T3 (es) 2014-10-30
ES2733841T3 (es) 2019-12-03
US20140323405A1 (en) 2014-10-30
DK2295126T3 (en) 2016-02-29
US7777006B2 (en) 2010-08-17
WO2004060528A1 (fr) 2004-07-22
US20150320846A1 (en) 2015-11-12
EP3543254A1 (fr) 2019-09-25
US11224643B2 (en) 2022-01-18
CA2511986C (fr) 2012-02-28

Similar Documents

Publication Publication Date Title
LU93072I2 (fr) Inhibiteur de la protéinase alpha-1 humaine
BR0308115B1 (pt) artigo de calÇado e mÉtodo de fabricaÇço de artigo de calÇado
NO20043695L (no) Selektive dipeptidinhibitorer av kallikrein
DE60325499D1 (de) Stufenlos veränderliches stufengetriebe
IS7434A (is) N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma
DE60319273D1 (de) Entzunderungsdüse
DE60336213D1 (de) Chirurgisches klammergerät
NO20043645L (no) Sykloalkylinhibitorer av kaliumkanal-funksjon
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
ATE370714T1 (de) Geformtes tampon
NO20044148L (no) Sammensetning og fremgangsmate for bronnrensing
EP1499336A4 (fr) Inhibiteurs de protease
EP1511488A4 (fr) Inhibiteurs humains d'adam 10
EP1474093A4 (fr) Inhibiteurs de granzyme b
DK1487541T3 (da) Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
EP1660436A4 (fr) Inhibiteurs de la cathepsine
EP1535609A4 (fr) Inhibiteur de l'activation de nf-kb
EP1477118A4 (fr) Ultrasonographe
EP1500371A4 (fr) Echographe
EP1485109A4 (fr) Traitement vasculaire
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
EP1613311A4 (fr) Inhibiteurs de hif-1
DE60219211D1 (de) Sterilisator
EP1500370A4 (fr) Ultrasonographe
ATE373648T1 (de) Nf-kappab-inhibitoren